Risk Factors for Metastatic Castration-Resistant Prostate Cancer (CRPC) Predict Long-Term Treatment with Docetaxel

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Kawahara, Takashi ^a   Miyoshi, Yasuhide ^b   Sekiguchi, Zenkichi ^a   Sano, Futoshi ^a   Hayashi, Narihiko ^a   Teranishi, Jun ichi ^b   Misaki, Hiroshi ^c   Noguchi, Kazumi ^b   Kubota, Yoshinobu ^a   Uemura, Hiroji ^a  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^c Yamato City Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; DOCETAXEL; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; BONE METASTASIS; CANCER HORMONE THERAPY; CANCER RISK; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; HIGH RISK PATIENT; HUMAN; INTERSTITIAL PNEUMONIA; JAPANESE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; PREDICTION; RISK ASSESSMENT; SENSORY NEUROPATHY; SHORT COURSE THERAPY; STOMATITIS; TREATMENT DURATION; VISCERAL METASTASIS;

AGED; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; DEXAMETHASONE; DRUG RESISTANCE, NEOPLASM; HUMANS; KAPLAN-MEIER ESTIMATE; LONG-TERM CARE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEUTROPENIA; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; TAXOIDS; TREATMENT OUTCOME;

EID: 84868115358     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048186     Document Type: Article

References (16)

1. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, et al. (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502-1512.
2. Cooperberg MR, Hinotsu S, Namiki M, Ito K, Broering J, et al. (2009) Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy. J Clin Oncol 27: 4306-4313.
3. Huggins C, Hodges CV, (1972) Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 22: 232-240.
4. Millikan RE, (1999) Chemotherapy of advanced prostatic carcinoma. Semin Oncol 26: 185-191.
5. Tabernero J, Climent MA, Lluch A, Albanell J, Vermorken JB, et al. (2004) A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 15: 1358-1365.
6. Camps C, Massuti B, Jimenez A, Maestu I, Gomez RG, et al. (2006) Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial. Ann Oncol 17: 467-472.
7. Gridelli C, Gallo C, Di Maio M, Barletta E, Illiano A, et al. (2004) A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. Br J Cancer 91: 1996-2004.
8. Gervais R, Ducolone A, Breton JL, Braun D, Lebeau B, et al. (2005) Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol 16: 90-96.
9. Armstrong AJ, Tannock IF, de Wit R, George DJ, Eisenberger M,et al. The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. Eur J Cancer 46: 517-525.
10. Miyoshi Y, Uemura H, Nakamura M, Hasumi H, Sugiura S, et al. (2005) Treatment of androgen-independent, hormone-refractory prostate cancer with docetaxel in Japanese patients. Int J Clin Oncol 10: 182-186.
11. Pond GR, Armstrong AJ, Wood BA, Brookes M, Leopold L, et al. (2012) Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer. Eur Urol 61: 363-369.
12. Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, et al. (2003) Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 21: 1232-1237.
13. Kamiya N, Suzuki H, Endo T, Yano M, Naoi M, et al. (2012) Clinical usefulness of bone markers in prostate cancer with bone metastasis. Int J Urol.
14. Shimazui T, Kawai K, Miyanaga N, Kojima T, Sekido N, et al. (2007) Three-weekly docetaxel with prednisone is feasible for Japanese patients with hormone-refractory prostate cancer: a retrospective comparative study with weekly docetaxel alone. Jpn J Clin Oncol 37: 603-608.
15. Naito S, Tsukamoto T, Koga H, Harabayashi T, Sumiyoshi Y, et al. (2008) Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter Phase II trial in Japan. Jpn J Clin Oncol 38: 365-372.
16. Chevalier-Larsen ES, O'Brien CJ, Wang H, Jenkins SC, Holder L, et al. (2004) Castration restores function and neurofilament alterations of aged symptomatic males in a transgenic mouse model of spinal and bulbar muscular atrophy. J Neurosci 24: 4778-4786.